# Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis

> **NCT00762463** · PHASE3 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 240 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Diclofenac SR

## Key facts

- **NCT ID:** NCT00762463
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-06
- **Final completion:** 2010-08
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2021-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00762463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00762463, "Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00762463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*